phase readout
saveNCT06627647: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
RECRUITINGupdated 1mo ago
community read0 votes
Sponsor: AstraZeneca. Phase: PHASE3. Conditions: Non-squamous Non-small Cell Lung Cancer
view source ↗
comments(0)
5-min edit window · permanent after that